08/07/2026
LSU Health New Orleans-led research presented at highlights the performance of BloodSTOP® iX Trauma Matrix when normal clotting is impaired.
In large-animal models anticoagulated with Plavix or heparin, Trauma Matrix achieved:
· 100% hemostasis
· 100% survival and 0% mortality
By comparison, QuikClot® Combat Gauze achieved 25% hemostasis and experienced 50% mortality.
Across all four severe-bleeding models, Trauma Matrix also reduced blood loss and maintained 100% survival through 16 hours.
The research was selected for both poster and podium presentation at MHSRS 2026. These preclinical findings support further evaluation of Trauma Matrix for severe trauma and combat-related bleeding.
Read the full news:
https://lifescienceplus.com/lsu-health-study-finds-bloodstop-ix-trauma-matrix-improves-hemorrhage-control-and-survival-presented-at-mhsrs-2026/